Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq advance as soft inflation tempers Fed rate-hike bets
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 12c
August 5, 2020 4:03 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.16, $0.12 better than the analyst estimate of $0.04. Revenue for the quarter came in at $62.21 million versus the consensus estimate of $61.95 million.
Key Financial and Corporate Highlights
Total revenues from HETLIOZ® and Fanapt® were $62.2 million in the second quarter of... More